DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors' reply

Affiliations

¹ Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands.
² Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.
³ Department of Gastrointestinal Oncology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
⁴ Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.
⁵ Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands.
⁶ Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, 3584 CG Utrecht, Netherlands. Electronic address: j.schellens@gmail.com.

Comment

Linda M Henricks et al. Lancet Oncol. 2019 Feb.

. 2019 Feb;20(2):e67.

doi: 10.1016/S1470-2045(19)30010-5.

¹ Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands.
² Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.
³ Department of Gastrointestinal Oncology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
⁴ Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.
⁵ Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands.
⁶ Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, 3584 CG Utrecht, Netherlands. Electronic address: j.schellens@gmail.com.

No abstract available

Comment on

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM. Henricks LM, et al. Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348537
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how?
Lam KO, Tong CC, Lee VHF, Luk MY, Lam CW. Lam KO, et al. Lancet Oncol. 2019 Feb;20(2):e66. doi: 10.1016/S1470-2045(18)30867-2. Lancet Oncol. 2019. PMID: 30712799 No abstract available.